Panitumumab Journal Article


Authors: Saltz, L.; Easley, C.; Kirkpatrick, P.
Article Title: Panitumumab
Abstract: In September 2006, panitumumab (Vectibix; Amgen), a fully human antibody against the epidermal growth factor receptor (EGFR), was approved by the FDA for the treatment of patients with EGFR-expressing metastatic colorectal cancer with disease progression on or following fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy regimens.
Keywords: cancer survival; clinical trial; bevacizumab; erlotinib; fluorouracil; cancer combination chemotherapy; cancer growth; drug efficacy; drug safety; monotherapy; nonhuman; antineoplastic agents; drug approval; colorectal cancer; cancer immunotherapy; metastasis; lung non small cell cancer; receptor, epidermal growth factor; antineoplastic activity; food and drug administration; cetuximab; irinotecan; panitumumab; drug hypersensitivity; colorectal neoplasms; antibodies, monoclonal; add on therapy; folinic acid; neoplasm metastasis; colon carcinoma; oxaliplatin; rectum carcinoma; fluoropyrimidine; drug indication; vectibix
Journal Title: Nature Reviews Drug Discovery
Volume: 5
Issue: 12
ISSN: 1474-1776
Publisher: Nature Publishing Group  
Date Published: 2006-12-01
Start Page: 987
End Page: 988
Language: English
DOI: 10.1038/nrd2204
PUBMED: 17201026
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 20" - "Export Date: 4 June 2012" - "CODEN: NRDDA" - "Source: Scopus"
Altmetric
Citation Impact
MSK Authors
  1. Leonard B Saltz
    760 Saltz